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A focus of tissue necrosis increases renal susceptibility to
gentamicin administration
RICHARD A. ZAGER
Department of Medicine, University of Washington, Seattle, Washington, USA
A focus of tissue necrosis increases renal susceptibility to gentamicin
administration. The purpose of this study was to determine whether a
retained focus of necrotic tissue predisposes to aminoglycoside-induced
acute renal failure (ARF). Rats were subjected to either (1) 25% liver
ligation, creating a focus of ischemic tissue which was left in place; (2)
25% liver resection; or (3) sham liver ligation. Gentamicin, 80 mg/kg
bid, was administered for two days after surgery to all three groups. A
fourth group was subjected to 25% liver ligation but no gentamicin
therapy, Only rats subjected to partial liver ligation plus gentamicin
treatment developed ARF, manifested by azotemia (BUN 80 2;
creatinine 1.63 0.21; mg/dl) and tubular necrosis. This occurred in the
absence of any discernible reduction in arterial blood pressure, renal
blood flow, excessive weight loss, or ascites formation. The partial liver
ligation-gentamicin group had 70% higher renal gentamicin concentra-
tions than the liver resection-gentamicin controls (P = 0.01). To assess
whether factors released from necrotic liver might account for these
findings, additional rats were infused with: (1) 1 ml of a soluble liver
extract alone; (2) 1 ml of liver extract plus gentamicin; or (3) 1 ml of
saline plus gentamicin. Only the liver extract/gentamicin group devel-
oped ARF (BUN 88 13; creatinine 1.46 0.25). This occurred in
association with a 110% increase in renal gentamicin uptake (P < 0.03).
In separate experiments, 5 ml liver extract infusions caused ARF (BUN
118 7; creatinine 2.1 0.18) without gentamicin treatment. In
conclusion, a focus of liver necrosis can predispose to experimental
gentamicin nephrotoxicity. This effect appears to be mediated by
increased renal gentamicin uptake and possibly by release of nephro-
toxic factors from necrotic tissue.
Aminoglycosides are widely regarded as one of the most
common causes of clinical acute renal failure (ARF) 1, 2].
Therefore, the pathophysiology of their renal toxicity has been
extensively investigated. Virtually all experimental studies of
this issue have been conducted in healthy laboratory animals.
Since patients who receive these agents are critically ill, inves-
tigations performed in normal animals may have limited clinical
relevance. For example, it typically takes 5 to 10 days of
aminoglycoside administration to induce ARF in healthy rats
[3—5]. However, if rats are rendered bacteremic, a single dose of
aminoglycoside can induce ARF within 24 hours [6]. This type
of observation underscores the necessity of defining the influ-
ence of clinical disease processes on the expression of drug
toxicity.
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A characteristic finding in critically ill patients is that they are
highly catabolic and have foci of tissue necrosis. Classic exam-
ples are acute pancreatitis, post-operative states, and septic
shock. However, the influence of retained necrotic tissue on the
expression of aminoglycoside nephrotoxicity has not been
defined. It is conceivable that necrotic tissue could release toxic
products into the circulation which could either induce direct
renal injury in conjunction with aminoglycosides or increase
renal aminoglycoside uptake. If so, then a focus of tissue
necrosis could represent a significant risk factor for amino-
glycoside administration.
The goal of this study was to seek experimental support for
this hypothesis. An intraabdominal focus of tissue necrosis was
created in rats by ligating approximately 25% of the liver,
insufficient to induce hepatic insufficiency. The effect of this
retained tissue on the expression of gentamicin nephrotoxicity
was then assessed.
Methods
General procedures
All experiments were performed on female Sprague-Dawley
rats (175 to 200 grams; Tyler Laboratories, Bellevue, Washing-
ton, USA) which were maintained under standard laboratory
conditions. Pentobarbital anesthesia (30 mg/kg) was used and
all surgical protocols were conducted on a heat controlled
surgical table to maintain body temperature between 36 and
37°C. Blood urea nitrogen (BUN) and plasma creatinine (Cr)
concentrations were determined on 300 rl tail vein plasma
samples by autoanalyzer technology. Direct mean arterial blood
pressure (MAP) measurements were made via a femoral artery
catheter, connected to a Gould Statham pressure transducer/
Comptel-Sensotec recorder [6, 7]. Left renal blood flow (RBF)
was measured by electromagnetic flow probe technology [8].
Renal histologic evaluations were performed on kidneys which
had been fixed by in vivo perfusion with 1.25% glutaraldehyde
in phosphate buffer saline [8]. The tissues were post-fixed in
10% buffered formaldehyde. Four micron paraffin embedded
sections were stained with hematoxylin and eosin.
In-vivo liver necrosis protocols
Partial liver necrosis protocol. Eighteen rats underwent a
midline laparotomy to expose the liver. Two liver lobes, located
just below and close to the midline incision, were individually
encircled in silk ligatures which were pulled tight close to the
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origin of their vascular supply at the porta hepatis. The liver
lobes were left in place to serve as a nidus of ischemic tissue.
This approximated 25% of the total liver mass, or about 2.5 g of
tissue. Following the above surgical protocol the rats were
sutured. Immediately thereafter, gentamicin, 80 mg/kg, was
injected intramuscularly (i.m.). The rats were allowed to re-
cover from anesthesia and free access to food and water was
provided. Approximately 6, 24, and 32 hours following comple-
tion of the first gentamicin injection repeat doses of gentamicin,
80 mg/kg, were administered. Renal function was assessed by
measuring BUN and plasma Cr concentrations just before
surgery and at 24 and 48 hours following surgery. Immediately
after the final BUN and creatinine determination, five rats
underwent MAP and left RBF measurements for 20 minutes,
five rats underwent in vivo renal perfusion fixation for his-
tologic evaluation, and nine rats had their kidneys frozen and
saved for renal gentamicin determinations.
Control groups. The data from the above rats were compared
to that obtained from three sets of controls. (1) Sham surgery-
gentamicin treatment: 11 rats were subjected to a sham-liver
ligation surgical protocol. This was conducted identically to the
above protocol except that liver ligation was not performed.
Following surgery they received gentamicin exactly as de-
scribed above. BUN and Cr concentrations were determined
before, 24, and 48 hr following surgery. Five of these rats had
MAP and left RBF determined at 48 hr. Five rats underwent in
vivo renal perfusion fixation for histologic evaluation. (2) Partial
liver resection-gentamicin treatment: To differentiate the effects
of liver necrosis from a reduction in functional liver mass, eight
rats were subjected to the liver ligation protocol as noted above
except that immediately following ligature placement the ische-
mic lobes were resected as close as possible to the suture line.
Then the rats were treated exactly as noted above, receiving
gentamicin and undergoing serial BUN/Cr determinations. For-
ty-eight hours after surgery the kidneys from six of these rats
were removed and frozen for subsequent gentamicin assay. (3)
Partial liver necrosis—no gentamicin treatment: To assess the
effects of partial liver necrosis on the kidney independent of
gentamicin administration, five rats were subjected to the liver
ligation protocol as noted above but they received no gentami-
cm treatment. BUN/Cr concentrations were measured over 48
hours as noted above. At the end of the 48 hours the ligated
liver lobes were resected, fixed in 10% formaldehyde by immer-
sion, and 4 micron paraffin embedded sections were stained
with hematoxylin and eosin.
Renal hemodynamics/volume effects. The effects of liver
necrosis on renal hemodynamics were assessed at two points in
time. As noted above, RBF and MAP were determined in five
partial liver necrosis-gentamicin treated rats and in five sham
surgery-gentamicin treated rats 48 hours after surgery. Addi-
tional studies were conducted at 24 hours: 5 rats were subjected
to the partial liver necrosis protocol and 5 to the partial liver
resection protocol. They received the first two gentamicin
injections as previously described, and 24 hours after surgery
RBF and MAP were determined.
Despite the fact that RBF and MAP were found to be normal
in the above hemodynamic experiments (Results), the following
protocol was conducted to assess whether more subtle differ-
ences in intravascular volume, not reflected by MAP or RBF,
might have existed between groups, possibly raising plasma
gentamicin concentrations independently of any developing
ARF. Ten rats were weighed and tail vein blood BUN, Cr, and
hematocrits were determined. The rats were then equally
divided into liver ligation and liver resection groups. It had
previously been determined that all the weight loss induced by
the surgical protocols occurs within the first 18 to 24 hours
post-surgery. Thus, if intravascular volume depletion were to
occur, it should have been maximal at this time. Therefore, at
22 hours post-surgery repeat weights were obtained and then
the rats were injected for the first time with gentamicin, 80
mg/kg. Exactly two hours later the rats were phlebotomized
from the inferior vena cava, having been anesthetized immedi-
ately before. The vena cava blood was used to determine
central hematocrits, plasma gentamicin concentrations, and
BUN and Cr concentrations. In addition, the plasma Mg ,and
K concentrations were determined, the latter because hypo-
kalemia may accelerate the development of gentamicin nephro-
toxicity [9].
Renal gentamicin concentrations. Renal gentamicin concen-
trations were compared between 9 partial-liver necrosis rats
and 6 partial-liver resection rats as delineated above. One
kidney per rat was homogenized and solubilized with Triton
bOx as previously described [6]. Gentamicin concentrations
were determined by fluorescence polarization [61 (TDX; Abbott
Laboratories, Irving, Texas, USA) and the values were ex-
pressed as g/g of tissue wet weight. Plasma samples were
diluted 1:10 prior to assay.
Histology. The degree of tubular necrosis was compared at 48
hours between five sham surgery-gentamicin treated rats and
five partial liver necrosis-gentamicin treated rats. The 10 kidney
histology slides from each of these two groups were coded and
the degree of necrosis was graded semiquantitatively on a scale
of 0 to 5+. Zero equalled no necrosis and 5 equalled extensive
necrosis, being observed in approximately one of every four
high-powered microscopic fields (box). Scores of 1 to 4
represented intermediate grades of necrosis. The distribution of
scores between the two groups were compared by Wilcoxon
rank sum test.
Experiments using soluble liver extract
The following experiments were performed to determine
whether liver contains a factor which, with release into the
circulation, can cause acute tubular injury.
Liver extract preparations. Normal rat livers were excised
and maintained ex vivo for 60 minutes at 37°C, simulating warm
ischemic conditions. Then, one part of the liver was homoge-
nized with one part normal saline. The homogenate was centri-
fuged, once at 1,500 g x 20 minutes at 4°C, and twice at 65,000
g x 20 minutes at 4°C, the latter to pellet membrane fragments
and intracellular organelles. The supernatant was divided into
three parts: (1) One part was kept frozen until further use; (2)
one part was dialyzed for 18 hours at 4°C against normal saline,
using 10,000 molecular weight exclusion dialysis tubing; and (3)
one part was dialyzed as above using 50,000 molecular-weight
exclusion dialysis-tubing.
Renal effects of liver extract infusion. Five ml of each
preparation was infused individually into anesthetized rats via a
jugular venous catheter over 60 minutes (N = 5, 2, and 2 for
preparations 1, 2, and 3, respectively). Then, the rats were
allowed to recover from anesthesia without further interven-
86 Zager: Aminoglycoside nephrotoxicity
Table L Degrees of azotemia in response to gentamicin administration
Group N
Basline 24 hr 48 hr
BUN Cr BUN Cr BUN Cr
1. Sham surgery—
gentamicin 11 18 1 0.53 0.01 22 2 0.60 0.01 23 1 0.59 0.02
2. Liver resection—
gentamicin 8 19 1 0.56 0.03 20 1 0.65 0.01 29 3 0.72 0.05Pvs.1 NS NS NS NS NS NS
3. Liver necrosis—
gentamicin 18 17 1 0.53 0.01 26 3 0.67 0.10 80 2 1.63 0.21
P vs. 1 NS NS NS NS <0.01 <0,01
P vs. 2 NS NS NS NS <0.01 <0.01
4. Liver necrosis—
no gentamicin 5 18 1 0.52 0.02 16 2
(NS)
0.65 0.02
(NS)
20 3
(NS)
0.66 0.07
(NS)
Comparisons between groups 1, 2, and 3 are by two-way ANOVA for repeated measures with aftertesting by Student's Newman Keuls for
repeated measures. The P values given in the Table are for comparisons between the groups. Over time: Group 1 showed no significant rise of BUN
or Cr over the 48 hr. Group 2 had a significant rise in BUN and Cr (P < 0.05) by 48 hr. Group 3 had a significant rise in BUN and Cr (P < 0.01) by 48
hr. Group 4 (not included in above analysis because it did not receive gentamicin) had no significant rise in the BUN or Cr over 48 hr (by one-way
ANOVA for repeated measures).
BUN, creatinine (Cr) = mg/dl.
tions. BUN and plasma Cr concentrations were determined
before and 24 hours after these infusions. At 24 hours, MAP
was measured for 20 minutes and the kidneys were fixed for
histology.
To assess acute hemodynamic responses to i.v. infusion of
liver extract, 4 rats received a 5 ml i.v. infusion of the
undialyzed preparation over 60 minutes. During this time MAP
and RBF were monitored continuously.
Assessment of whether liver extract potentiates gentamicin
toxicity. Three groups of rats were established: (1) 1 ml
undialyzed liver extract infused i.v. over one hour followed
immediately by gentamicin treatment, 80 mglkg i.m. (N =7),
This gentamicin dose was repeated four hours later. (2) 1 ml of
liver extract infused i.v. over one hour with no gentamicin
treatment (N = 7). (3) 1 ml of i.v. saline, followed immediately
by gentamicin treatment as noted above (N = 6). The severity
of renal injury was assessed by measuring the BUN/Cr concen-
trations before and 24 hours after these procedures. Then, the
kidneys from all rats treated with gentamicin were removed and
assayed for gentamicin concentrations.
Statistics
All values are given as means SEM. Statistical comparisons
of BUNs and Cr were made by two analysis of variance for
repeated measures (ANOVA) with after testing by Student
Newman Keuls for repeated measures. Other data were com-
pared by one way ANOVA, unpaired Student's t-test, or
Wilcoxon rank sum test (histology) as stated in Results. Signif-
icance was judged by a P value of <0,05.
Results
In vivo liver necrosis protocols
Renal functional data (Table 1). The sham operated rats
treated with gentamicin developed no significant elevations in
the BUN (23 1) and Cr (0.59 0.02) concentrations (mg/dl)
over the 48 hour protocol. The liver resection-gentamicin
treated rats developed only slight azotemia by 48 hours (BUN
29 3; Cr 0.72 0.05; P < 0.05 compared to baseline) although
these values were not significantly higher than those of the
sham operated-gentamicin treated group. In contrast, the rats
with liver necrosis-gentamicin treatment developed severe
azotemia by the end of the experiments (BUN 80 2; Cr 1.63
0.21; P < 0.01 compared to the other groups and to baseline
values). Liver necrosis—no gentamicin therapy induced no
significant azotemia (BUN 20 3; Cr 0.66 0.07)by the end of
the 48 hours protocol (one way ANOVA for repeated mea-
sures).
The sham operated rats lost 12 2 g of body weight over 48
hours. The weight loss in the liver resection-gentamicin group
and the liver necrosis-gentamicin group were 17 2 and 16 2
g, respectively. These values were not statistically different
(one way ANOVA). No correlation between the degree of
weight loss and the rise in BUN was observed, in the liver
necrosis-gentamicin treated group (r = 0.098). There was no
obvious ascites formation in any of the groups.
Histology. Renal histology confirmed increased renal injury
in the rats injected with gentamicin in the presence of necrotic
liver. The partial liver necrosis-gentamicin treated rats had
widespread foci of proximal tubular necrosis particularly in the
cortex but also in the outer medullary stripe (Fig. 1). All
histologic scores for these rats were 3 with a mean value of 4.5
0.2. The necrotic debris gave rise to extensive cast formation
in proximal tubular segments. In contrast, the sham operated-
gentamicin treated rats had only rare foci of proximal tubular
necrosis, all scores being 2 (mean 1.4 0.2; P < 0.01
compared to the above group, Fig. 2). Thus, there was a
complete separation of histologic scores for the two groups (2
or 3). Hyaline cast formation was rarely seen in either group
of kidneys. The vasculature and glomerull appeared normal in
both groups.
The liver lobes resected 24 hours after their ligation revealed
firm pale tissue without evidence of abscess formation. No
ascites was present. Histology of the ligated lobes showed
diffuse necrosis, the hepatocytes appearing as ghost cells. No
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Fig. 1. Liver necrosis/gentamicin: extensive proximal tubular necrosis is apparent with large amounts of necrotic tubular debris lying in tubular
lumina. (Cortex/outer medulla; tissue fixed at 48 hi; xl 12).
Fig. 2. Sham surgery/genlamicin administration: no proximal tubular necrosis is observed. (Cortex; tissue fixed at 48 hr; xl 12).
polymorphonuclear cell infiltration was seen. Early metastatic
calcification was observed in the subcapsular region.
Renal hemodynamics/volume effects. RBF and MAP 24
hours after surgery did not significantly differ (unpaired Stu-
dent's t-test) between the liver necrosis-gentamicin treated rats
(RBF 5.9 0.5 ml/min; MAP 121 4 mm Hg) and the liver
resection-gentamicin treated controls (RBF 5.0 0.5; MAP 120
5). Similarly, no significant differences in either RBF or MAP
were apparent 48 hours after surgery in the liver necrosis-
gentamicin treated rats (RBF 5.1 0.3; MAP 115 6) and the
sham surgery-gentamicin controls (RBF 5.3 0.3; MAP 122
4).
The separate experiments to measure central hematocrits
(Hct) at 24 hours post-surgery, the time of maximal weight loss,
showed no significant difference between the liver ligation (42
1%) and liver resection (41 1%) groups. The baseline tail vein
Hcts were 45 1% and 44 1% in the resection and ligation
groups, respectively. Body weight loss for the liver ligation and
liver resection groups were 14 1 g (ligation) and 15 2 g
(resection) (NS). No pre-renal azotemia developed in either
group (ligation: baseline BUN/Cr, 21 3/0.56 0.04; 24 hr 17
1/0.56 0.04; resection: baseline 19 1/0.54 0.06; 24 hr 18
2/0.60 0.03 mg/dl). Plasma gentamicin concentrations did
not significantly differ between the liver ligation (25 5 tWm1)
Wt Jc•JJ# 'tf'4 .. •• _,'• •,.
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FIg. 3. Renal histology 24 hours after 5 ml liver extract infusion demonstrating foci of proximal tubular necrosis with necrotic debris lying within
multiple tubular segments. (Inner cortex; x200).
Table 2. One ml ilver extract int'usi on experiments
Group N
Baseline 24 hr after treatment
BUN Cr [gentamicin]'BUN Cr
1.
2.
3.
Liver extract
alone 1 ml
Gentamicin alone
Liver extract 1 ml
plus gentamicin
P vs. 1 and 2
7
6
7
20 1
23 3
18 1
NS
0.64 0.02
0.55 0.03
0.57 0.04
NS
26 3
24 2
88 13
<0.01
0.61 0.02
0.67 0.02
1,46 0.25
<0.01
N/A
322 36
677 128
<0.03
a sg/g tissue wet weight. BUN, creatinine (Cr) = mg/dl.
N/A not applicable.
BUN and Cr values are compared by two-way analysis of variance with aftertesting (for repeated measures) by Newman Keuls. The gentamicin
concentrations are compared by unpaired Student's f-test.
and liver resection (29 6) rats. The plasma K and Mg
concentrations for the liver ligation rats were 3.5 0.1 and 1.5
0.08 mEq/liter, respectively. These did not significantly differ
from the values observed in the liver resection controls (K 3.4
0.4; Mg 1.5 0.03).
Renal gentamicin concentrations. The rats with partial liver
resection treated with gentamicin had 48-hour renal gentamicin
concentrations of 602 35 gIg tissue wet weight. The renal
gentamicin concentrations in the partial liver necrosis group
was approximately 70% higher (1021 110;P = 0.01; unpaired
Student's t-test). The large degree of variation in the latter
group (range 555 to 1442) directly correlated with the BUN
concentrations (r 0.75; P < 0.02).
Liver extract infusion experiments
Five ml liver extract infusion experiments. All rats infused
with S ml of liver extract, whether dialyzed or undialyzed,
developed acute renal failure, all BUN and Cr values being 98
mg/dl and 1.8 mgldl, respectively. The mean values for the
rats infused with undialyzed extract were BUN 110 7 and Cr
1.9 0.22. The means for the rats infused with the dialyzed
preparations were BUN 127 11 and Cr 2.4 0.24. The liver
extract infusion caused no acute reduction in either RBF or
MAP, all values being >4.6 ml/min (RBF) and >115 mm Hg
during the entire one-hour infusion experiments, both normal
values [7, 8]. Twenty-four hours after extract infusion, MAP
was still normal (122 7) despite the renal failure.
Renal histology 24 hours after liver extract infusion revealed
scattered foci of proximal tubular necrosis, most prominent in
the cortex (Fig. 3). Necrotic tubular cell debris was observed in
proximal tubular segments and, most prominently, in the inner
medulla and papilla. The same histologic findings were ob-
served in all kidneys irrespective of whether they received
dialyzed or undialyzed extracts. Occasional hyaline casts were
observed. Glomeruli appeared normal.
One ml liver extract-gentamicin experiments (Table 2). One
ml liver extract infusion alone induced no significant rise in the
BUN or Cr concentration. Gentamicin treatment alone induced
no azotemia. However, 1 ml liver extract plus gentamicin
induced renal failure, the BUN and Cr rising to 88 13 and 1.46
0.25 mgldl, respectively. Renal gentamicin concentrations 24
hours after treatment were significantly higher in the rats which
'S
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had received liver extract infusion (677 128 jsg/g), compared
to the gentamicin treated rats infused with saline (322 36; P <
0.03) (unpaired t-test). The renal gentamicin concentrations in
the liver extract-infused group strongly correlated with the 24
hour BUN concentrations (r = 0.91; P < 0.02).
Discussion
The results of these investigations indicate that a focus of
necrotic liver can enhance experimental aminoglycoside
nephrotoxicity. By 48 hours following the surgical protocol,
rats subjected to partial liver necrosis and gentamicin treatment
manifested severe renal failure whereas the sham-operated
controls treated with gentamicin developed no significant
azotemia. Renal histology confirmed greater renal injury in the
liver necrosis group, revealing extensive proximal tubular ne-
crosis and cast formation. Conversely, only minimal histologic
damage was observed in the sham operated-gentamicin group.
These findings indicate that the observed differences in renal
function between these two groups had a structural and not just
a hemodynamic basis. This point is substantiated by the hemo-
dynamic assessments performed on these two groups of rats 48
hours after surgery, since no difference in either RBF or MAP
existed. In fact, despite the severe ARF in the liver necrosis
group, RBF was 5.1 mllmin, a normal value.
The results of the liver resection-gentamicin protocol indicate
that it is the presence of necrotic tissue and not just a reduction
in functional hepatic mass which is responsible for the potenti-
ation of gentamicin toxicity. These rats developed only slight
elevations of the BUN and Cr concentrations (compared to
their baseline values), and these values did not significantly
exceed those observed in the sham operated-gentamicin con-
trols. Given the fact that it is impossible to totally resect all
necrotic liver because a small cuff of tissue must be left at the
suture line, it is not surprising that a slight rise in the BUN and
Cr occurred in this liver resection group.
To evaluate whether liver necrosis alone might be responsible
for the ARF which followed the liver necrosis-gentamicin
protocol, renal function was assessed in rats subjected to partial
liver necrosis without gentamicin treatment. All rats survived
this protocol and no azotemia developed. Examination of the
liver lobes 48 hours after their ligation revealed firm pale tissue
without evidence of abscess formation. No ascites was present
in this or any other group. Microscopic examination of the
involved lobes showed only necrotic hepatocytes and early
secondary calcification. No white cell infiltration was observed.
Thus, infection is an extremely unlikely explanation for the
renal failure which resulted in the liver necrosis-gentamicin
group. This point is underscored by the fact that since overt
infection did not occur with liver necrosis in the absence of
antibiotics it was even less likely to have developed in the
presence of gentamicin therapy.
One possible mechanism by which liver necrosis could have
exacerbated gentamicin toxicity is by enhancing renal gentami-
cm uptake. The liver necrosis-gentamicin group had 70% higher
renal gentamicin concentrations than the liver resection group.
The strong correlation between the BUN and the renal genta-
micin concentrations (r 0.75) suggests that a causal relation-
ship could have existed. The mechanism for the increased
gentamicin uptake is unknown. Intravascular volume depletion
leading to enhanced tubular uptake [10] is an unlikely explana-
tion for a number of reasons: (1) MAP and RBF were normal at
both 24 and 48 hours after surgery in the liver ligation group,
excluding hemodynamically significant intravascular volume
depletion; (2) no elevation of the BUN or Cr developed in liver
ligation rats not treated with gentamicin, thereby excluding a
significant pre-renal component; (3) no significant elevation in
the central hematocrit was observed in the liver ligation rats at
24 hours, the time of maximal weight loss; (4) no significant
difference in weight loss existed among the experimental
groups, and yet only the liver ligation-gentamicin group devel-
oped ARF; (5) no correlation (r =0.098) between the amount of
weight loss (range 13 to 22 g) and the 48 hour BUNs (range 42
to 162 mg/dl) existed for the liver ligation-gentamicin group; had
weight loss/volume depletion been key factors in renal genta-
micin uptake and the induction of ARF, a strong correlation
should have existed; and (6) plasma gentamicin concentrations
two hours after its injection were comparable in liver ligation
and liver resection rats. Since the rats used for these experi-
ments did not have ARF, comparable plasma concentrations
suggest comparable extracellular fluid volumes. Although it is
still possible that subtle differences in volume status could have
existed between the rats, the above considerations make major
volume disturbances an unlikely explanation for the results of
these experiments. A possible non-volume mediated reason for
the increased gentamicin uptake could be that necrotic liver
releases a factor into the circulation which enhances renal
gentamicin accumulation. Some support for this hypothesis is
presented below. Finally, it remains possible that the increased
renal gentamicin uptake was primarily a result of the renal
failure and not the proximate cause of it. A decrease in
glomerular filtration rate would lead to higher plasma gentami-
cm concentrations and a more prolonged gentamicin half-life.
These factors would then be expected to increase renal genta-
micin accumulation, forming an amplification loop to the renal
injury.
A second possible mechanism by which liver necrosis might
potentiate gentamicin nephrotoxicity is by releasing nephrotox-
ic factors into the circulation which act in concert with genta-
micin to induce renal failure. The liver extract infusion exper-
iments provide support for this hypothesis. Five ml liver extract
infusions induced tubular necrosis and ARF without having any
deleterious effect on MAP or RBF. When 1 ml of this extract
was administered, no renal failure resulted. However, when 1
ml was administered with gentamicin, renal failure was pro-
duced. This indicates that the liver extract given in a
subnephrotoxic dose is capable of precipitating gentamicin
nephrotoxicity. Liver extract infusion also increased renal
gentamicin uptake. Thus, these results are analogous to those
found in the in vivo liver necrosis experiments: liver necrosis or
1 ml of liver extract alone does not cause renal failure; genta-
micin alone does not cause renal failure; however, when liver
necrosis or liver extract infusion occurs in the setting of
gentamicin therapy, renal failure results and it is associated
with increased renal gentamicin uptake. Although it is impos-
sible to be certain that the liver necrosis and liver extract-
induced potentiation of gentamicin nephrotoxicity have a com-
mon mechanism, the strong similarity of results suggest this
might well be the case.
The liver extract factor responsible for these effects remain
unknown. It appears to have a high molecular weight since its
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ability to induce renal failure was not diminished by 50,000
molecular-weight exclusion dialysis. Given this large size it
appears likely that the active factor is a protein. However, its
identity, whether it gains direct access to tubular cells, or
whether it evokes a systemic mediator of tubular injury remain
to be defined.
Because the present experiments were conducted using only
liver as the source of necrotic tissue, it is impossible to
conclude that tissue necrosis in general, rather than liver
necrosis in particular, potentiates gentamicin toxicity. The
reason that liver was chosen for experimentation is that a large
nidus of necrotic tissue could be created without inducing major
organ dysfunction, given the large amount of hepatic tissue
available. The only other tissue potentially available for study
would have been skeletal muscle. However, muscle ligation
would have resulted in myoglobinuria, a known cause of ARF
[7, 11, 121, thereby complicating data interpretation. Recent
clinical observations suggest that hepatic disease may predis-
pose to aminoglycoside nephrotoxicity [13—15], again raising
the question as to whether the present results were dependent
on using liver as the source of tissue injury. Thus, the question
of whether the current findings are hepatic specific or can be
reproduced by other types of necrotic tissue remains to be
defined.
In conclusion, these studies indicate that a retained focus of
necrotic liver can dramatically potentiate experimental amino-
glycoside nephrotoxicity. The data suggest that this effect is
mediated by endogenous nephrotoxic compounds released from
necrotic tissue and by increased renal gentamicin uptake. These
findings provide experimental support for the clinical notion
that the underlying medical condition of a patient at the time of
aminoglycoside administration, and not just drug dosage and
duration of treatment, determine whether ARF results.
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